Q3 2021 Investor Relations Results
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
CosentyxⓇ peak sales expectations of at least USD 7bn driven
by market growth, geographic expansion and LCM
In-market indications
USD 29bn market growing double-digit¹
Current biologics treated: 15% PsO,
13% axSpA, 23% PSA²
China
China post-NRDL acceleration
with potential to expand to
PsA and nr-axSpA
Lifecycle management
Expansion to 10+ potential indications:
Hidradenitis Suppurativa (Ph3 readout
Q4), GCA (Ph2 positive, Ph3 started),
Lichen Planus (Ph2), Lupus Nephritis
(Ph2)
Additional potential label
enhancements including i.v. for PsA
(Ph3 positive) & AS, 300mg
autoinjector, Pso flex dosing
People + excellence in operations
See appendix for references PSO-Psoriasis axSpA - axial Spondyloarthritis nr-axSpA - non-radiographic axial Spondyloarthritis PSA Psoriatic Arthritis NRDL - National Reimbursement Drug List AS - Ankylosing Spondylitis
26 Investor Relations | Q3 2021 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation